Nikolai
Sign out
Dashboard
Documents
Contacts
Settings
Welcome
Nikolai
Access the latest updates and key information on Nowwell’s technical, clinical and commercial progress.
Shareholder updates
Shareholder update
September 2026
Shareholder document
Latest news
May 15, 2026
Preclinical NowCath results presented at AUA
Steven Kaplan presented preclinical findings evaluating NowCath Foley in a validated glass bladder model.
May 14, 2026
Nowwell presented at AUA Innovation Nexus 2026
CEO Nikolai Hoffmann-Petersen introduced NowCath Foley and the REDUCE clinical trial at AUA Innovation Nexus 2026.
February 17, 2026
Anthony Campbell Appointed CCO
Nowwell welcomes Anthony Campbell as Chief Commercial Officer to lead the company’s commercial strategy and market development.
All materials are strictly confidential and intended for authorised shareholders only.
Any sharing, distribution, or reproduction of the content without prior written consent is strictly prohibited.